Related references
Note: Only part of the references are listed.Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
Cheng-Kuo Cheng et al.
BMC OPHTHALMOLOGY (2022)
Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy
Damian Jaggi et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2022)
Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting
Marko Lukic et al.
EUROPEAN JOURNAL OF OPHTHALMOLOGY (2021)
Imaging Biomarkers and Their Impact on Therapeutic Decision-Making in the Management of Neovascular Age-Related Macular Degeneration
David T. Wong et al.
OPHTHALMOLOGICA (2021)
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES Study: A Randomized Clinical Trial
Paul Mitchell et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)
Macular Atrophy in Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Mark C. Gillies et al.
OPHTHALMOLOGY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
Adam H. Ross et al.
EYE (2020)
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors
Jakob Siedlecki et al.
SCIENTIFIC REPORTS (2020)
Prevalence and Pattern of Geographic Atrophy in Asia The Asian Eye Epidemiology Consortium
Tyler Hyungtaek Rim et al.
OPHTHALMOLOGY (2020)
Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration A Prospective Study
Ichiro Maruko et al.
OPHTHALMOLOGY RETINA (2020)
Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study
Tso-Ting Lai et al.
SCIENTIFIC REPORTS (2019)
Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration
Sandra Aurell et al.
ACTA OPHTHALMOLOGICA (2019)
Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration
H. N. Tarakcioglu et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2019)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
TWO YEAR OUTCOMES OF TREAT AND EXTEND INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Daniel Barthelmes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Treat-and-extend versus every-other-month regimens with aflibercept in age-related macular degeneration
Akira Haga et al.
ACTA OPHTHALMOLOGICA (2018)
Age-related macular degeneration: using morphological predictors to modify current treatment protocols
Mohammed Ashraf et al.
ACTA OPHTHALMOLOGICA (2018)
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times
Sascha Fauser et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians
Chee Wai Wong et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2016)
Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration
Sebastian M. Waldstein et al.
JAMA OPHTHALMOLOGY (2016)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
Gui-shuang Ying et al.
OPHTHALMOLOGY (2013)
SYSTEMIC RISK FACTORS ASSOCIATED WITH POLYPOIDAL CHOROIDAL VASCULOPATHY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Yoichi Sakurada et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Asian Age-Related Macular Degeneration: Current Concepts and Gaps in Knowledge
Laurence Shen Lim et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2013)
Age-related macular degeneration
Laurence S. Lim et al.
LANCET (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Share Paper
